Does rifaximin offer any promise in Crohn's disease in remission and concurrent irritable bowel syndrome-like symptoms?
- Resource Type
- Authors
- Irina Magdalena Dumitru; Lucian Cristian Petcu; Cristina Tocia; Eugen Dumitru; Luana Alexandrescu
- Source
- Medicine
- Subject
- Adult
Male
medicine.medical_specialty
Abdominal pain
Remission, Spontaneous
Observational Study
Inflammatory bowel disease
Gastroenterology
Rifaximin
03 medical and health sciences
chemistry.chemical_compound
Feces
0302 clinical medicine
Bloating
Crohn Disease
Gastrointestinal Agents
inflammatory bowel disease
Internal medicine
medicine
Humans
030212 general & internal medicine
Irritable bowel syndrome
irritable bowel syndrome
Crohn's disease
business.industry
Microbiota
digestive, oral, and skin physiology
Endoscopy
General Medicine
Middle Aged
medicine.disease
digestive system diseases
Abdominal Pain
Diarrhea
C-Reactive Protein
chemistry
quality of life
030220 oncology & carcinogenesis
Female
Calprotectin
medicine.symptom
business
Leukocyte L1 Antigen Complex
Research Article
- Language
- English
- ISSN
- 1536-5964
0025-7974
Microbiota plays an important role in many diseases including inflammatory bowel diseases. Inflammatory bowel disease patients can have concurrent irritable bowel syndrome symptoms similar to those associated with a flare. The potential role of gut dysbiosis in the pathogenesis of inflammatory bowel disease provides a rationale for treating such patients with rifaximin. This study aimed to assess the efficacy of rifaximin in the management of irritable bowel syndrome-like symptoms (bloating, abdominal pain, stool consistency) and quality of life in patients with Crohn's disease in remission. The present study included 86 patients with Crohn's disease in remission (fecal calprotectin